Hidradenitis suppurativa
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Hidradenitis suppurativa (stadju I) fil-koxxa. Dan huwa każ ħafif ħafna ta' Hidradenitis suppurativa.
References
Hidradenitis suppurativa hija kundizzjoni tal-ġilda li hija kronika, tibqa’ terġa’ lura, u tista’ taffettwa ħajtek serjament. Hija kkawżata minn infjammazzjoni fil-follikuli tax-xagħar, u ħafna drabi twassal għal infezzjonijiet batteriċi. It-tobba normalment jiddijanjostikawha billi jħarsu lejn it-tipi ta’ feriti li għandek (bħal noduli, axxessi, jew passaġġi tas-sinus) , fejn ikunu (ġeneralment f’tinji tal-ġilda) , u kemm-il darba jiġu lura u kemm idumu jżommu.
Hidradenitis suppurativa is a chronic, recurrent, and debilitating skin condition. It is an inflammatory disorder of the follicular epithelium, but secondary bacterial infection can often occur. The diagnosis is made clinically based on typical lesions (nodules, abscesses, sinus tracts), locations (skin folds), and nature of relapses and chronicity.
Hidradenitis suppurativa is a chronic, recurrent, and debilitating skin condition. It is an inflammatory disorder of the follicular epithelium, but secondary bacterial infection can often occur. The diagnosis is made clinically based on typical lesions (nodules, abscesses, sinus tracts), locations (skin folds), and nature of relapses and chronicity.
Trattamenti mhux bijoloġiċi u mhux proċedurali huma komunement użati waħedhom għal mard ħafif u jistgħu jiġu kkombinati ma 'terapija bijoloġika u kirurġija għal mard moderat għal sever. Studji reċenti jipprovdu evidenza addizzjonali ta 'effettività għall-użu ta' kortikosterojdi injettati direttament fil-leżjonijiet għal flare-ups ta 'HS u leżjonijiet lokalizzati. Barra minn hekk, hemm evidenza li tissuġġerixxi li l-użu ta' tetracyclines waħdu jista' jkun effettiv daqs il-kombinazzjoni ta' clindamycin ma' rifampicin.
Non-biologic and non-procedural treatments are often used as monotherapy for mild disease and can be used in conjunction with biologic therapy and surgery for moderate to severe disease. Recent studies highlighted in this review add support for the use of intralesional corticosteroids for HS flares and localized lesions, and there is evidence that monotherapy with tetracyclines may be as effective as the clindamycin/rifampicin combination.
Non-biologic and non-procedural treatments are often used as monotherapy for mild disease and can be used in conjunction with biologic therapy and surgery for moderate to severe disease. Recent studies highlighted in this review add support for the use of intralesional corticosteroids for HS flares and localized lesions, and there is evidence that monotherapy with tetracyclines may be as effective as the clindamycin/rifampicin combination.
Ħafna trattamenti jintużaw għal hidradenitis suppurativa, inklużi antibijotiċi, retinojdi, antiandroġeni, mediċini li jrażżnu l-immunità, mediċini anti-infjammatorji, u radjuterapija għal leżjonijiet bikrija. L-aqwa trattamenti rakkomandati huma adalimumab u terapija bil-laser. Il-kirurġija, jew qtugħ sempliċi jew qtugħ lokali komplut bit-tilqim tal-ġilda, hija l-għażla preferuta għal każijiet severi u avvanzati li ma jirrispondux tajjeb għal trattamenti oħra.
Many treatments are used for hidradenitis suppurativa, including antibiotics, retinoids, antiandrogens, immune-suppressing drugs, anti-inflammatory medications, and radiotherapy for early lesions. The top recommended treatments are adalimumab and laser therapy. Surgery, either simple excision or complete local excision with skin grafting, is the preferred option for severe, advanced cases that don't respond well to other treatments.
Many treatments are used for hidradenitis suppurativa, including antibiotics, retinoids, antiandrogens, immune-suppressing drugs, anti-inflammatory medications, and radiotherapy for early lesions. The top recommended treatments are adalimumab and laser therapy. Surgery, either simple excision or complete local excision with skin grafting, is the preferred option for severe, advanced cases that don't respond well to other treatments.
Il-kawża eżatta hija ġeneralment mhux ċara, iżda maħsub li jinvolvi taħlita ta 'fatturi ġenetiċi u ambjentali. Madwar terz tan-nies bil-marda għandhom membru tal-familja affettwat. Fatturi ta’ riskju oħra jinkludu l-obeżità u t-tipjip. Il-kundizzjoni mhix ikkawżata minn infezzjoni, iġjene fqira.
L-ebda kura mhi magħrufa. It-tqattigħ miftuħin tal-leżjonijiet biex jippermettulhom ixxotta ma jirriżultax f'benefiċċju sinifikanti. Filwaqt li l-antibijotiċi huma komunement użati, l-evidenza għall-użu tagħhom hija fqira. Medikazzjoni immunosoppressiva tista' wkoll tiġi ppruvata. F'dawk b'mard aktar gravi, terapija bil-laser jew kirurġija biex titneħħa l-ġilda affettwata jistgħu jkunu vijabbli. Rarament, leżjoni tal-ġilda tista' tiżviluppa f'kanċer tal-ġilda.
Jekk jiġu inklużi każijiet ħfief ta ' hidradenitis suppurativa , allura l-istima tal-frekwenza tagħha hija minn 1-4% tal-popolazzjoni. In-nisa huma tliet darbiet aktar probabbli li jiġu dijanjostikati biha mill-irġiel. Il-bidu huwa tipikament fiż-żgħir.